Accelerating Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelerating Drug Development
FDA's new safety program, Critical Path Initiative, and user-fee proposal seek to reinvigorate pharmaceutical R&D.


Pharmaceutical Technology


More disclosure

The FDA plan addresses many of the IOM recommendations for improving how it assesses and communicates risk information, although not always in the way the expert panel suggested. Experts have clamored for FDA to make public more drug-safety information from postapproval studies and adverse-event reports, but industry has opposed the idea of posting emerging safety information before it is fully evaluated by sponsors and regulators. Instead of launching a "Drug Watch" Web site that would have posted emerging safety information, FDA now proposes to publish an on-line newsletter with summaries of FDA postmarketing drug reviews, new safety concerns, and information about newly approved products. The postings will be cleansed of confidential commercial information, however, and FDA does not plan to disclose supplement reviews.


Fees for safety
Instead of establishing some kind of conditional approval for new drugs, which probably requires legislative change, FDA is launching a pilot plan to re-evaluate newly approved drugs after a year on the market. The agency will review adverse-event reports and additional information for two or three NMEs in a pilot program that will issue its first assessments in about 18 months. The reports will be made public, and the pilot could be extended to all new drugs if it succeeds in providing a more complete picture of safety issues throughout the product life cycle.

A central issued raised by the IOM is that CDER's pro-approval culture relegated safety reviewers to a secondary role in evaluating the risks and benefits of new drugs. Galson plans organizational changes that will give CDER's Office of Surveillance and Epidemiology staff a clear role in approving new drug applications (NDAs) and requesting postmarket studies and future label changes. Each new drug-review office will have a high-level safety manager, and a new electronic tracking system will integrate multiple agency databases.

A leading legislative proposal requires all NDAs to include risk-management plans, and the IOM report urges further evaluation of such approaches. FDA says it will assess the effectiveness of RiskMAPS and publicly review one or two risk programs every year to better determine whether RiskMAPS or other approaches can improve public awareness of serious safety issues.

FDA also is expanding programs to use emerging electronic health-information systems to gain more information about drug use and health outcomes. The agency is collaborating with the Veterans Administration, Medicare, and other government agencies to access data on medical-product use in federal healthcare systems. A proposed FDA Sentinel Network would link private and public databases to establish a national medical-product safety network.

Stress on science

An underlying theme of FDA's drug-safety program is that new developments in biomedical science can detect risk issues early in development. FDA Deputy Commissioner Janet Woodcock, now the agency's chief medical officer, heads a range of efforts to accelerate risk assessment by sponsors and FDA, many launched under the Critical Path Initiative.

For example, FDA is collaborating with industry and academia about developing new tests for organ toxicity and for identifying the cardiovascular risk of drugs. The Predictive Safety Consortium is sharing data to crossvalidate preclinical safety biomarkers. Another consortium of manufacturers, FDA, and the National Institutes of Health (NIH) plans to assess biomarkers that can spur development of new treatments, beginning with lung cancer and lymphoma. And, a new Serious Adverse Event Consortium seeks to identify and validate genetic variants that may help predict the risk of drug-induced reactions, starting with liver disease and serious skin rashes.

These efforts to improve clinical-program success rates and reduce development time and cost were described in FDA's Critical Path Opportunities List, which was issued in March 2006 and updated in a January 2007 report on collaborations and research activities undertaken in 2006. The aim is to "build safety into products" by better understanding the genetic basis of adverse events, explained Woodcock. These approaches can screen out toxic compounds early on and identify patients most likely to have adverse events—or to respond well—to a test medicine. FDA, she said, wants to "make products safer from the get-go."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here